{
    "clinical_study": {
        "@rank": "50294", 
        "arm_group": {
            "arm_group_label": "Afatinib treatment", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Advanced lung cancer (non-small cell lung cancer) with a mutation in the EGFR (epidermal\n      growth factor receptor) gene, which have disease progression after treatment with an EGFR\n      inhibitor (erlotinib or gefitinib), and have progression of disease also after treatment\n      with chemotherapy will be recruited. The trial has only one arm, of afatinib daily\n      treatment. Blood and exhaled breath samples will be collected for investigations aiming to\n      identify factors that predict response to afatinib."
        }, 
        "brief_title": "An Open Label Study of BIBW 2992/Afatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib", 
        "condition": "NSCLC", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Advanced NSCLC\n\n          -  EGFR mutation or six months or longer benefit from EGFR TKIs\n\n          -  Disease progression on chemotherapy, or inability to receive chemotherapy for medical\n             reasons.\n\n          -  Disease progression on EGFR TKI, or the presence of an EGFR mutation that does\n             predicts for poor response to first generation EGFR TKIs.\n\n        Exclusion Criteria:\n\n          -  Inability to take oral drugs"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01932229", 
            "org_study_id": "SHEBA-12-9547-JB-CTIL"
        }, 
        "intervention": {
            "arm_group_label": "Afatinib treatment", 
            "intervention_name": "Afatinib treatment", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Gefitinib", 
                "Erlotinib"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Advanced NSCLC", 
            "EGFR mutation", 
            "TKIs", 
            "Tyrosine Kinase Inhibitors"
        ], 
        "lastchanged_date": "August 29, 2013", 
        "location": {
            "contact": {
                "email": "Diana.Vorenshtein@sheba.health.gov.il", 
                "last_name": "Dina Vornstein"
            }, 
            "facility": {
                "address": {
                    "city": "Ramat Gat", 
                    "country": "Israel", 
                    "zip": "52621"
                }, 
                "name": "Sheba Medical Center"
            }, 
            "investigator": {
                "last_name": "Jair Bar, MD-PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open Label Study of BIBW 2992/Afatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib", 
        "overall_contact": {
            "last_name": "Jair Bar, MD-PhD", 
            "phone": "+972-3-530-7096"
        }, 
        "overall_contact_backup": {
            "email": "Diana.Vorenshtein@sheba.health.gov.il", 
            "last_name": "Dina Vornstein, B.A."
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression free survival", 
            "safety_issue": "No", 
            "time_frame": "One year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01932229"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Overall survival", 
            "safety_issue": "Yes", 
            "time_frame": "One year"
        }, 
        "source": "Sheba Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sheba Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}